ArticleCureus2025
Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Due to Trimethoprim: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare, severe, and potentially life-threatening drug hypersensitivity reaction characterized by cutaneous eruption, hematologic abnormalities, and internal organ involvement. Early recognition and prompt withdrawal of the culprit drug are crucial to reduce morbidity and mortality. We report a case of a 17-year-old woman with a psychiatric history who presented with a progressive maculopapular rash, fever, cough, and lethargy after initiation of trimethoprim for acne. Examination revealed a diffuse rash and bilateral chest crepitations. Laboratory studies showed elevated inflammatory markers, eosinophilia, and deranged liver function tests. Imaging demonstrated bilateral pulmonary infiltrates. Initial improvement was noticed with oral steroids, but her symptoms recurred on withdrawal. After which, corticosteroids were introduced, but despite this, her respiratory function deteriorated, necessitating intensive care admission. Microbiological investigations were negative for infection. Based on clinical features and drug association, along with European Registry of Severe Cutaneous Adverse Reaction Criteria (RegiSCAR) scoring, a diagnosis of DRESS syndrome secondary to trimethoprim, further complicated by pneumonitis, was made. The patient was treated with systemic corticosteroids with gradual clinical and biochemical improvement over six weeks. This case highlights trimethoprim as a potential but under-recognized trigger for DRESS syndrome. Early identification, discontinuation of the offending drug, and careful use of corticosteroids are essential to prevent severe complications. Clinicians should maintain a high index of suspicion for DRESS in patients presenting with rash, fever, eosinophilia, and multiorgan involvement following recent drug exposure.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.